329 related articles for article (PubMed ID: 35843774)
21. Mesenchymal stem cells and their derived exosomes to combat Covid-19.
Yousefi Dehbidi M; Goodarzi N; Azhdari MH; Doroudian M
Rev Med Virol; 2022 Mar; 32(2):e2281. PubMed ID: 34363275
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in mesenchymal stem cell-based therapy for acute lung injury.
Liang J; Dai W; Xue S; Wu F; Cui E; Pan R
Cell Tissue Bank; 2024 Jun; 25(2):677-684. PubMed ID: 38466563
[TBL] [Abstract][Full Text] [Related]
23. Visualized Analyses of Investigations Upon Mesenchymal Stem/stromal Cell-based Cytotherapy and Underlying Mechanisms for COVID-19 Associated ARDS.
Aitong W; Leisheng Z; Hao Y
Curr Stem Cell Res Ther; 2022; 17(1):2-12. PubMed ID: 34254927
[TBL] [Abstract][Full Text] [Related]
24. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
Front Immunol; 2022; 13():932360. PubMed ID: 35860245
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
Barros I; Silva A; de Almeida LP; Miranda CO
Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
[TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.
Yao W; Shi L; Zhang Y; Dong H; Zhang Y
Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737
[TBL] [Abstract][Full Text] [Related]
29. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
[TBL] [Abstract][Full Text] [Related]
30. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
[TBL] [Abstract][Full Text] [Related]
31. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19.
Cai Q; Yin F; Hao L; Jiang W
Stem Cells Dev; 2021 May; 30(9):459-472. PubMed ID: 33715385
[TBL] [Abstract][Full Text] [Related]
32. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
Kaye RJ
Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
[TBL] [Abstract][Full Text] [Related]
33. Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.
Rocha JLM; de Oliveira WCF; Noronha NC; Dos Santos NCD; Covas DT; Picanço-Castro V; Swiech K; Malmegrim KCR
Stem Cell Rev Rep; 2021 Feb; 17(1):71-93. PubMed ID: 32895900
[TBL] [Abstract][Full Text] [Related]
34. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.
Chouw A; Milanda T; Sartika CR; Kirana MN; Halim D; Faried A
Regen Eng Transl Med; 2022; 8(1):43-54. PubMed ID: 33723519
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
Pourgholaminejad A; Pahlavanneshan S; Basiri M
Scand J Immunol; 2022 Feb; 95(2):e13131. PubMed ID: 34936112
[TBL] [Abstract][Full Text] [Related]
36. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.
Wang XY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4537-4538. PubMed ID: 32373992
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
Harrell CR; Jovicic BP; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
[TBL] [Abstract][Full Text] [Related]
39. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
[TBL] [Abstract][Full Text] [Related]
40. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.
Heidari F; Heidari R; Sabet MN; Hamidieh AA; Saltanatpour Z
Curr Stem Cell Res Ther; 2024; 19(5):644-652. PubMed ID: 37073149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
